Novel protein, CYP4V2-KLKB1 readthrough (CYP4V2-KLKB1 readthrough)

The CYP4V2-KLKB1 readthrough refers to a non-canonical, chimeric transcript produced by transcriptional readthrough between the adjacent CYP4V2 and KLKB1 genes on chromosome 4. Both parent genes contribute coding potential in other form: - **CYP4V2** encodes a cytochrome P450 omega-hydroxylase involved in fatty acid metabolism, with loss-of-function mutations causing Bietti crystalline corneoretinal dystrophy[4]. - **KLKB1** encodes plasma kallikrein, a serine protease key to kinin generation, blood coagulation, and inflammatory pathways, with mutations leading to prekallikrein deficiency[3]. The readthrough transcript is not associated with established biological functions, disease roles, or known drug interactions, and is not considered a therapeutic target. Its annotation in databases reflects transcriptomics findings rather than protein functionality or clinical relevance[2]. Key clarification: - This entry is not a therapeutic target. - The readthrough is primarily a *genomic annotation artifact* and not a functionally validated molecule. - For therapeutic interest, refer separately to CYP4V2 (a cytochrome P450 enzyme) or KLKB1 (plasma kallikrein, a serine protease)[2][3][4]. If you require information on CYP4V2 or KLKB1 individually, detailed canonical entries can be provided.

Other names

ENSG00000290316CYP4V2-KLKB1 readthrough